!["I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/11e93c561a9ff98f731b152d7f48e6f792831864-1000x1000.jpg?w=350&fit=crop&auto=format)
Oncology NEWS International
- Oncology NEWS International Vol 19 No 6
- Volume 19
- Issue 6
Cleveland Clinic nets federal funds for research facility revamp
The Taussig Cancer Institute at the Cleveland Clinic has been awarded more than $2 million from the American Recovery and Reinvestment Act for the renovation and expansion of its translational cancer research facilities. The National Center for Research Resources, which is part of NIH, awarded the grant.
DEREK RAGHAVEN, MD, PHD
The Taussig Cancer Institute at the Cleveland Clinic has been awarded more than $2 million from the American Recovery and Reinvestment Act for the renovation and expansion of its translational cancer research facilities. The National Center for Research Resources, which is part of NIH, awarded the grant.
The funds will be used to update 3,600 square feet of laboratory space that was built on the clinic's main campus in 1928. The space was last renovated in the 1950s. Renovations will include a shared instrumentation room that will free up an additional 500 square feet to allow for more bench research.
The expanded laboratory area also will allow for the recruitment of up to four new independent researchers, a dozen technical support positions, and an administrative assistant.
"The expansion of our translational cancer research capabilities is essential to the mission of the Taussig Cancer Institute," said Derek Raghavan, MD, PhD, chair of the institute, in a written statement. "This award will allow us to continue to bring the latest research straight from the lab to the bedside to aid in the diagnosis and treatment of patients."
Articles in this issue
about 16 years ago
Nobel laureate heads up NCIabout 16 years ago
Diabetes drug acts as chemopreventive in smokersabout 16 years ago
FTC extends deadline for Red Flags Rule on patient privacyabout 16 years ago
Breakthrough cancer-related pain: The truth hurtsabout 16 years ago
African-American genetic mutations pose Rx challengeabout 16 years ago
Personalized medicine advances in non-small–cell lung cancer treatmentabout 16 years ago
PET unable to reliably identify post-Rx colon mets





















































